



(Formerly known as Intercontinental Leasing & Finance Company Limited)

CIN: L24100GJ1984PLC111413

Reg. Office : 501, Aditraj Arcade, Near Hetvi Tower, Opp. Titanium City Center, 100 Ft. ring road, Satellite, Ahmedabad -380015.

**Date: 12<sup>th</sup> November, 2021**

To,

Listing Compliances, <b>BSE Limited,</b> P. J. Towers, Fort, Mumbai - 400001. <b>Scrip Code: 539938; Scrip Id: MIL</b>	Listing Compliances, <b>CSE - India,</b> 7, Lyons Range, Dalhousie Kolkata - 700001.
--	---

**Subject: Outcome of Board Meeting and Compliances of Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.**

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., November 12, 2021, inter alia, considered and approved unaudited Standalone and Consolidated Financial Results, Statement of Assets & Liabilities and Cash Flow Statement of the Company for the quarter and half year ended on September 30, 2021 along with Limited Review Report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.

Further, please find enclosed "Standalone and Consolidated Unaudited Financial Results, Statement of Assets & Liabilities and Cash Flow Statement along with Limited Review Report" for the quarter and half year ended on September 30, 2021 and same is also available on the website of the Company viz. [www.medicointercontinental.com](http://www.medicointercontinental.com)

The Board Meeting of the Company commenced at 11:30 A.M. and concluded at 01:40 P.M.

This is for your information and records.

Thanking You,

**For Medico Intercontinental Limited**



**Puneeta Sharma**  
**Company Secretary & Compliance Officer**

Encl: As stated



3, SF, Manek Apartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended)**

TO THE BOARD OF DIRECTORS OF **MEDICO INTERCONTINENTAL LIMITED**

We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company"), for the quarter ended September 30, 2021 ("the Statement") and year to date from April 01, 2021 to September 30, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, **V. GOSWAMI & CO,**  
Chartered Accountants  
(FRN: 0128769W)

Nilesh Purohit  
(Partner)  
Mem. No: 162541  
Date: - 12/11/2021  
Place:-Ahmedabad  
UDIN: 21162541AAAAEN8021





**MEDICO INTERCONTINENTAL LIMITED**  
CIN NO: L24100GJ1984PLC111413  
Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN  
Tel No. 079-26742739 E-mail: mail@medicointercontinental.com Website: www.medicointercontinental.com  
Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2021


		Quarter Ended			Half Year Ended		Year Ended
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended
Sr. No.	Particulars	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Revenues</b>							
1	Revenue from Operations	1012.78	1122.47	1106.57	2135.25	2473.58	4102.21
2	Other Income	3.90	1.07	4.53	4.97	15.73	16.43
3	<b>Total Revenue (A)</b>	<b>1016.68</b>	<b>1123.54</b>	<b>1111.10</b>	<b>2140.22</b>	<b>2489.31</b>	<b>4118.63</b>
<b>Expenses</b>							
(a)	Cost of materials consumed	0.00	0.000	0.00	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	869.82	897.23	949.67	1767.04	2272.06	3678.12
(c)	Changes in inventories of finished goods and stock-in-trade	-17.75	110.58	32.88	92.82	-74.95	-99.79
(d)	Employee benefits expense	20.98	18.05	21.23	39.03	41.87	85.81
(e)	Finance costs	9.13	18.22	21.47	27.36	41.80	77.91
(f)	Depreciation and amortisation expense	2.61	2.38	1.38	4.99	2.47	6.26
(g)	Other expenses	86.75	32.18	41.79	118.93	121.35	204.32
	<b>Total Expenses (B)</b>	<b>971.53</b>	<b>1078.64</b>	<b>1068.41</b>	<b>2050.18</b>	<b>2404.60</b>	<b>3952.62</b>
5	<b>Profit/(Loss) before exceptional items &amp; tax (1-4)</b>	<b>45.14</b>	<b>44.90</b>	<b>42.69</b>	<b>90.04</b>	<b>84.71</b>	<b>166.01</b>
6	<b>Exceptional items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
7	<b>Profit/(Loss) for the period from operations before tax (5+6)</b>	<b>45.14</b>	<b>44.90</b>	<b>42.69</b>	<b>90.04</b>	<b>84.71</b>	<b>166.01</b>
8	<b>Tax expense</b>	<b>11.48</b>	<b>11.43</b>	<b>10.63</b>	<b>22.91</b>	<b>20.99</b>	<b>46.51</b>
(a)	Current Tax	11.83	11.76	10.68	23.59	21.18	47.02
(b)	Deferred Tax	-0.35	-0.33	-0.05	-0.68	-0.19	-0.51
9	<b>Profit/(Loss) for the period from continuing operations (7-8)</b>	<b>33.67</b>	<b>33.47</b>	<b>32.06</b>	<b>67.13</b>	<b>63.72</b>	<b>119.50</b>
10	<b>Profit/(loss) for the period from discontinued operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
11	<b>Tax expense of discontinued operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
12	<b>Profit/(loss) for the period from Discontinued operations (after tax)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
13	<b>Profit/ (loss) for the period (After tax)</b>	<b>33.67</b>	<b>33.47</b>	<b>32.06</b>	<b>67.13</b>	<b>63.72</b>	<b>119.50</b>
14	<b>Other Comprehensive Income</b>						
	Other comprehensive Income/(Loss)	0.00	0.00	0.00	0.00	0.00	0.00
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>33.67</b>	<b>33.47</b>	<b>32.06</b>	<b>67.13</b>	<b>63.72</b>	<b>119.50</b>
	Paid-up Equity Share Capital (Face Value INR 10 each)	324.90	324.90	324.90	324.90	324.90	324.900
16	<b>Earnings Per Equity Share of Rs. 10 each (for continuing Operations)</b>						
(a)	Basic - INR	1.04	1.03	0.99	2.07	1.96	3.68
(b)	Diluted - INR	1.04	1.03	0.99	2.07	1.96	3.68
17	<b>Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)</b>						
(a)	Basic - INR	0.00	0.00	0.00	0.00	0.00	0.000
(b)	Diluted - INR	0.00	0.00	0.00	0.00	0.00	0.000
18	<b>Earnings Per Equity Share of Rs. 10 each (for continuing &amp; discontinuing Operations)</b>						
(a)	Basic - INR	1.04	1.03	0.99	2.07	1.96	3.68
(b)	Diluted - INR	1.04	1.03	0.99	2.07	1.96	3.68

- The above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 12, 2021. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The Company has considered possible effects that may result from COVID-19 in preparation of these results including recoverability of assets including inventories and trade receivables. In developing the assumptions relating to future uncertainties in the economic conditions due to COVID-19, it has, at the date of approval of these results, used relevant internal and external sources of information including economic forecasts and expects that the carrying amounts of these assets are recoverable. The impact of COVID-19 may be different from that estimated as at the date of approval of these standalone financial results.
- During the quarter ended September 30, 2021, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.
- The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.
- The previous period figures have been re-grouped / reclassified, wherever considered necessary.

Place:- Ahmedabad  
Date:-12/11/2021

For and on behalf of Board of Directors of  
Medico Intercontinental Limited

SAMIR SHAH  
MANAGING DIRECTOR  
DIN: 03350268



**MEDICO INTERCONTINENTAL LIMITED**

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN  
Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

**Unaudited Standalone Statement of Assets and Liabilities as at 30 September, 2021**

		(Rs in Lakhs)	
Particulars		As at 30.09.2021	As at 31.03.2021
		Unaudited	Audited
<b>A.</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	Property, Plant and Equipments		
	Financial Assets	22.87	24.03
	(i) Investments		
	Deferred Tax Assets (Net)	420.19	435.19
	Other Non-Current Assets	2.42	1.74
	<b>Total Non-Current Assets</b>		
<b>2</b>	<b>Current assets</b>	445.48	460.96
	Inventories		
	Financial Assets	262.79	355.61
	(i) Trade receivables		
	(ii) Cash and Cash Equivalents	775.69	803.45
	(iii) Loans	443.34	11.58
	Other Current Assets	-	-
	<b>Total Current Assets</b>	4.16	10.49
	<b>TOTAL ASSETS</b>	<b>1,485.98</b>	<b>1,181.12</b>
<b>B.</b>	<b>EQUITY AND LIABILITIES</b>	<b>1,931.46</b>	<b>1,642.08</b>
<b>1</b>	<b>Equity</b>		
	Equity Share Capital		
	Other Equity	324.90	324.90
	<b>Total Equity</b>	376.23	309.10
	<b>Liabilities</b>	<b>701.13</b>	<b>634.00</b>
<b>2</b>	<b>Non-Current Liabilities</b>		
	Financial Liabilities		
	(i) Borrowings		
	<b>Total Non-Current Liabilities</b>	706.66	478.39
<b>3</b>	<b>Current Liabilities</b>	<b>706.66</b>	<b>478.39</b>
	Financial Liabilities		
	(i) Borrowings		
	(ii) Trade Payables	3.24	3.24
	Due to Micro and Small Enterprises	-	-
	Due to others	241.65	238.71
	(iii) Other Financial Liabilities	221.42	263.10
	Other Current Liabilities	-	-
	Provisions	53.12	3.53
	<b>Total Current Liabilities</b>	4.24	21.11
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>523.66</b>	<b>529.69</b>
		<b>1,931.46</b>	<b>1,642.08</b>

For and on behalf of Board of Directors of  
MEDICO INTERCONTINENTAL LIMITED



SAMIR SHAH  
MANAGING DIRECTOR  
DIN: 03350268



Place:- Ahmedabad  
Date:-12/11/2021



**MEDICO INTERCONTINENTAL LIMITED**  
CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN  
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com  
**Unaudited Standalone Cash Flow Statement for the half year ended 30 September, 2021**

		(Rs in Lakhs)	
	PARTICULARS	Half year ended 30.09.2021 (Unaudited)	Half year ended 30.09.2020 (Unaudited)
<b>A.</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES :</b>		
a)	Net Profit/ (Loss) before tax	90.04	84.70
b)	<b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>	<b>90.04</b>	<b>84.70</b>
	<u>Adjustments For:</u>		
	Depreciation	4.99	2.47
	Finance costs	27.36	39.07
	Interest and Dividend Income	-0.50	-1.40
	<b>CASH GENERATED FROM OPERATIONS</b>	<b>121.89</b>	<b>124.84</b>
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	92.82	-74.95
	Decrease/(Increase) in Trade Receivables	27.75	163.58
	Decrease/(Increase) in Other Current assets	6.33	-10.69
	Increase/(Decrease) in Provisions	0.00	2.69
	Increase/(Decrease) in Trade Payables	-38.75	49.93
	Increase/(Decrease) in Current Financial Liabilities - Borrowings	0.00	0.00
	Increase/(Decrease) in Other Current Liabilities	49.59	-3.62
	<b>CASH GENERATION FROM OPERATING ACTIVITY</b>	<b>259.64</b>	<b>251.76</b>
	Income Tax Paid Net	(40.46)	-35.42
	<b>NET CASH FROM/(USED IN) OPERATING ACTIVITIES</b>	<b>219.18</b>	<b>216.34</b>
<b>B.</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Purchase of Fixed Assets	-3.83	-8.46
	Decrease/(Increase) in Investment	15.00	-62.99
	Interest and Dividend Income	0.50	1.40
	<b>NET CASH FROM/(USED IN) INVESTING ACTIVITIES</b>	<b>11.67</b>	<b>-70.04</b>
<b>C.</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Increase/(Decrease) in Loans and Advances	0.00	0.00
	Proceed from /(Repayment) of Borrowings net	228.27	-107.30
	Proceed from /(Repayment) of Short Term Borrowings net	0.00	0.00
	Finance Costs paid	-27.36	-39.07
	<b>NET CASH FROM/(USED IN) FINANCING ACTIVITIES</b>	<b>200.92</b>	<b>-146.37</b>
	<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>431.76</b>	<b>-0.07</b>
	<b>CASH AND CASH EQUIVALENTS (At the beginning of the year)</b>	<b>11.58</b>	<b>13.79</b>
	<b>CASH AND CASH EQUIVALENTS (At the end of the year)</b>	<b>443.34</b>	<b>13.72</b>

For and on behalf of Board of Directors of  
MEDICO INTERCONTINENTAL LIMITED

Place:- Ahmedabad  
Date:- 12/11/2021

  
SAMIR SHAH  
MANAGING DIRECTOR  
DIN: 03350268





3, SF, Manek Appartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

TO THE BOARD OF DIRECTORS OF **MEDICO INTERCONTINENTAL LIMITED**

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2021 ("the Statement") and year to date from April 01, 2021 to September 30, 2021 attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement included the results of following subsidiary company:-

1. EVAGRACE PHARMA PRIVATE LIMITED
2. RITZ FORMULATIONS PRIVATE LIMITED
3. SUNGRACE PHARMA PRIVATE LIMITED
4. AZILLIAN HEALTHCARE PRIVATE LIMITED

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





**V.GOSWAMI & CO.**  
**CHARTERED ACCOUNTANTS**

PEER REVIEW :- 011190

ISO 9001:2015 CERTIFIED

MSME :- GJ01D0134595

GST : 24AAHFV3075F1Z7

3, SF, Manek Appartment, Nr. Jain Derasar, Above Dena Bank, Nehrunagar Circle, Ahmedabad-380015.  
M : +91 94287 33427 | E-mail : thegoswami@gmail.com | canilesh.vgc@gmail.com | www.goswami.in

We did not review the interim financial results of the subsidiaries included in the consolidated unaudited financial results, whose financial results and other unaudited financial information reflects total assets of Rs. 1868.86 Lakhs as at September 30, 2021, total revenues of Rs. 972.89 Lakhs and Rs. 2508.72 Lakhs and total net profit Rs. 40.69 Lakhs and Rs. 81.22 Lakhs for quarter ended September 30, 2021 and for the period from April 01, 2021 to September 30, 2021, respectively, net cash inflow of Rs. 16.99 Lakhs for the period from April 01, 2021 to September 30, 2021, respectively as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,  
Chartered Accountants  
(FRN: 0128769W)

Nilesh Purohit  
(Partner)

Mem. No.: 162541

Date:-12/11/2021

Place: - Ahmedabad

UDIN: 21162541AAAAE08404






MEDICO INTERCONTINENTAL LIMITED							
CIN NO: L24100GJ1984PLC111413							
Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN							
Tel No. 079-26742739		E-mail:- mail@medicointercontinental.com		Website: www.medicointercontinental.com			
Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2021							
(Rs in Lakhs)							
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	<b>Revenues</b>						
1	Revenue from Operations	1864.93	2355.39	1917.84	4220.32	3904.09	6974.05
2	Other Income	3.98	1.07	4.53	5.05	17.55	17.84
3	<b>Total Revenue (A)</b>	<b>1868.90</b>	<b>2356.46</b>	<b>1922.37</b>	<b>4225.36</b>	<b>3921.64</b>	<b>6991.89</b>
	<b>Expenses</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	1436.79	1774.40	1623.42	3211.19	3428.72	5805.24
	(c) Changes in inventories of finished goods and stock-in-trade	63.44	187.97	-23.94	251.41	-153.04	-43.38
	(d) Employee benefits expense	51.52	42.33	50.10	93.85	108.91	217.39
	(e) Finance costs	21.33	28.71	33.01	50.04	66.39	127.99
	(f) Depreciation and amortisation expense	4.83	4.30	3.21	9.13	6.13	13.74
	(g) Other expenses	191.36	219.48	145.87	410.84	285.08	517.70
	<b>Total Expenses (B)</b>	<b>1769.28</b>	<b>2257.19</b>	<b>1831.67</b>	<b>4026.47</b>	<b>3742.19</b>	<b>6638.68</b>
5	<b>Profit/(Loss) before exceptional items &amp; tax (1-4)</b>	<b>99.63</b>	<b>99.27</b>	<b>90.70</b>	<b>198.90</b>	<b>179.45</b>	<b>353.21</b>
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit/(Loss) for the period from operations before tax (5+6)</b>	<b>99.63</b>	<b>99.27</b>	<b>90.70</b>	<b>198.90</b>	<b>179.45</b>	<b>353.21</b>
8	<b>Tax expense</b>	<b>25.27</b>	<b>25.27</b>	<b>22.79</b>	<b>50.54</b>	<b>45.02</b>	<b>95.59</b>
	(a) Current Tax	25.50	25.43	22.61	50.93	44.75	95.20
	(b) Deferred Tax	-0.23	-0.16	0.18	-0.39	0.27	0.39
9	<b>Profit/(Loss) for the period from continuing operations (7-8)</b>	<b>74.36</b>	<b>74.00</b>	<b>67.91</b>	<b>148.36</b>	<b>134.43</b>	<b>257.62</b>
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Profit/ (loss) for the period (After tax)</b>	<b>74.36</b>	<b>74.00</b>	<b>67.91</b>	<b>148.36</b>	<b>134.43</b>	<b>257.62</b>
14	Other Comprehensive Income						
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>74.36</b>	<b>74.00</b>	<b>67.91</b>	<b>148.36</b>	<b>134.43</b>	<b>257.62</b>
	Paid-up Equity Share Capital (Face Value INR 10 each)	324.900	324.900	324.900	324.900	324.900	324.90
16	<b>Earnings Per Equity Share of Rs. 10 each (for Continuing Operations)</b>						
	(a) Basic - INR	2.29	2.28	2.09	4.57	4.14	7.93
	(b) Diluted - INR	2.29	2.28	2.09	4.57	4.14	7.93
17	<b>Earnings Per Equity Share of Rs. 10 each (for Discontinuing Operations)</b>						
	(a) Basic - INR	0.000	0.000	0.000	0.000	0.000	0.00
	(b) Diluted - INR	0.000	0.000	0.000	0.000	0.000	0.00
18	<b>Earnings Per Equity Share of Rs. 10 each (for Continuing &amp; Discontinuing Operations)</b>						
	(a) Basic - INR	2.29	2.28	2.09	4.57	4.14	7.93
	(b) Diluted - INR	2.29	2.28	2.09	4.57	4.14	7.93

- The above unaudited Consolidated financial results of the Company for the quarter and half year ended September 30, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 12, 2021. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The Group has considered possible effects that may result from COVID-19 in preparation of these results including recoverability of assets including inventories and trade receivables. In developing the assumptions relating to future uncertainties in the economic conditions due to COVID-19, it has, at the date of approval of these results, used relevant internal and external sources of information including economic forecasts and expects that the carrying amounts of these assets are recoverable. The impact of COVID-19 may be different from that estimated as at the date of approval of these Consolidated financial results.
- During the quarter ended September 30, 2021, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.
- The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.
- The previous period figures have been re-grouped / reclassified, wherever considered necessary.

For, Medico Intercontinental Limited



SAMIR SHAH  
MANAGING DIRECTOR  
DIN: 03350268



Place:- Ahmedabad  
Date:- 12/11/2021



**MEDICO INTERCONTINENTAL LIMITED**

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015  
IN

Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

**Unaudited Consolidated Statement of Assets and Liabilities as at September 30, 2021**

(Rs in Lakhs)

	Particulars	As at 30.09.2021	
		Unaudited	Audited
<b>A. ASSETS</b>			
<b>1 Non-current assets</b>			
	Property, Plant and Equipment	122.35	121.17
	Intangible Assets	113.79	113.97
	Financial Assets	-	-
	(i) Investments	1.00	16.00
	(i)Loans	-	-
	(iii)Other financial assets	-	-
	Deffered tax assets (Net)	2.49	-
	Other non-current Assets	76.11	1.11
	<b>Total Non-Current Assets</b>	<b>315.74</b>	<b>252.25</b>
<b>2 Current assets</b>			
	Inventories	659.70	911.11
	Financial Assets		
	(i) Trade Receivables	1,933.82	1,797.82
	(ii) Cash and Cash Equivalents	500.23	51.48
	(iii) Loans	-	-
	Other Current Assets	17.29	51.87
	<b>Total Current Assets</b>	<b>3,111.04</b>	<b>2,812.28</b>
	<b>TOTAL ASSETS</b>	<b>3,426.77</b>	<b>3,064.53</b>
<b>B. EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
	Equity Share capital	324.90	324.90
	Other Equity	777.00	628.64
	<b>Total Equity</b>	<b>1,101.90</b>	<b>953.54</b>
<b>2 Non-Current Liabilities</b>			
	Financial Liabilities		
	(i) Borrowings	826.28	654.47
	Deferred tax liabilities (Net)	3.90	1.81
	Other non-current liabilities	0.35	0.35
	<b>Total Non-current liabilities</b>	<b>830.53</b>	<b>656.63</b>
<b>3 Current liabilities</b>			
	Financial Liabilities		
	(i) Borrowings	194.80	241.65
	(iii) Trade Payables	-	-
	Due to micor enterprises and small enterprises	241.65	238.71
	Due to others	795.71	816.48
	(iv) Other financial liabilities	18.63	34.64
	Other current liabilities	220.23	63.52
	Provisions	23.32	59.36
	<b>Total Current liabilities</b>	<b>1,494.34</b>	<b>1,454.36</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3,426.77</b>	<b>3,064.53</b>

For and on behalf of Board of Directors of  
MEDICO INTERCONTINENTAL LIMITED

  
  
**SAMIR SHAH**  
 MANAGING DIRECTOR  
 DIN:- 03350268

Place:-Ahmedabad  
Date:-12/11/2021

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Consolidated Cash Flow Statement for the half year ended 30 September, 2021

(Rs in Lakhs)

	PARTICULARS	Half year ended 30.09.2021 (Unaudited)	Half year ended 30.09.2020 (Unaudited)
A.	<b>CASH FLOW FROM OPERATING ACTIVITIES :</b>		
a)	Net Profit/ (Loss) before tax	198.90	179.46
b)	<b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>	<b>198.90</b>	<b>179.46</b>
	<u>Adjustments For:</u>		
	Depreciation	9.13	6.13
	Finance cost	50.04	66.39
	Interest received	-0.50	-1.40
	<b>CASH GENERATED FROM OPERATIONS</b>	<b>257.57</b>	<b>250.58</b>
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	251.41	-153.03
	Decrease/(Increase) in Trade Receivables	-136.00	164.74
	Decrease/(Increase) in Short Term Loan and Advances	0.00	0.00
	Decrease/(Increase) in Other Current Assets/Non Current Assets	-40.42	8.78
	Increase/(Decrease) in Provisions and Other Current Liabilities	120.68	25.86
	Increase/(Decrease) in Trade Payables	-17.83	66.93
	Increase/(Decrease) Current Financial Liabilities	-16.01	137.99
	<b>CASH GENERATION FROM OPERATING ACTIVITY</b>	<b>419.39</b>	<b>501.83</b>
	Income tax Paid Net	(50.93)	-65.01
	<b>NET CASH FROM/(USED IN) OPERATING ACTIVITIES</b>	<b>368.46</b>	<b>436.82</b>
B.	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Purchase of Fixed and Intangible assets	-10.13	-68.35
	Purchase/Sale Investments	15.00	-1.00
	Payment for Intangible Assets	0.00	0.00
	Deposits (net)	-	0.00
	Interest and Dividend Income	0.50	1.40
	<b>NET CASH FROM/(USED IN) INVESTING ACTIVITIES</b>	<b>5.37</b>	<b>-67.94</b>
C.	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Increase/(Decrease) in Loan and Advances	0.00	6.72
	Proceed from /(Repayment) of Long Term Borrowing net	171.81	-312.26
	Proceed from /(Repayment) of Short Term Borrowing net	-46.85	0.00
	Finance Costs paid	-50.04	-66.39
	<b>NET CASH FROM/(USED IN) FINANCING ACTIVITIES</b>	<b>74.92</b>	<b>-371.92</b>
	<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>448.75</b>	<b>-3.05</b>
	<b>CASH AND CASH EQUIVALENTS (At the beginning of the year)</b>	<b>51.48</b>	<b>77.88</b>
	<b>CASH AND CASH EQUIVALENTS (At the end of the year)</b>	<b>500.23</b>	<b>74.83</b>

For and on behalf of Board of Directors of  
MEDICO INTERCONTINENTAL LIMITED

Place:-Ahmedabad  
Date:-12/11/2021

SAMIR SHAH  
MANAGING DIRECTOR  
DIN: 03350268

